SCHEMBL5160772

SCHEMBL5160772

NC(=O)CC(=O)c1ccoc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.54
TRPA1 O75762 1/20 0.51
RAB9A P51151 2/20 0.41
ALOX5 P09917 2/20 0.41
NPC1 O15118 1/20 0.41
CHRNB2 P17787 1/20 0.39
CHRNB4 P30926 1/20 0.39
CHRNA3 P32297 1/20 0.39
CHRNA7 P36544 1/20 0.39
CHRNA4 P43681 1/20 0.39
KCNK3 O14649 1/20 0.39
KCNK9 Q9NPC2 1/20 0.39
MAPT P10636 2/20 0.39
GPR52 Q9Y2T5 1/20 0.38
PTK2 Q05397 1/20 0.38
PTPN1 P18031 1/20 0.38
PTPN6 P29350 1/20 0.38
PTPN11 Q06124 1/20 0.38
POLB P06746 1/20 0.36
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4995985 0.82 TRPA1 (0.53) CYP3A4TRPA1RAB9ANPC1CHRNB2
SCHEMBL10811976 0.80 TRPA1 (0.56) CYP3A4TRPA1RAB9ANPC1CHRNB2
SCHEMBL3705840 0.79
SCHEMBL15988633 0.79 TRPA1 (0.69) CYP3A4TRPA1RAB9AALOX5NPC1
Hydrochloric Acid SCHEMBL9372749 0.78 TRPA1 (0.53) CYP3A4TRPA1RAB9AALOX5NPC1
SCHEMBL4459301 0.77 TRPA1 (0.53) CYP3A4TRPA1RAB9ANPC1KCNK3
SCHEMBL7100741 0.77 TRPA1 (0.53) CYP3A4TRPA1RAB9ACHRNB2CHRNB4
SCHEMBL826974 0.76
SCHEMBL5161108 0.76 TRPA1 (0.51) CYP3A4TRPA1RAB9AALOX5CHRNB2
SCHEMBL12430461 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO CYP3A4 7/4885TRPA1 4224/4885RAB9A 3428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.